{"id":5312,"date":"2014-11-29T11:13:01","date_gmt":"2014-11-29T11:13:01","guid":{"rendered":"\/?p=5312"},"modified":"2014-11-29T11:26:17","modified_gmt":"2014-11-29T11:26:17","slug":"tapimmune-inc-otcmktstpiv-stirred-up-by-the-media","status":"publish","type":"post","link":"\/articles\/tapimmune-inc-otcmktstpiv-stirred-up-by-the-media\/","title":{"rendered":"TapImmune Inc. (OTCMKTS:TPIV) Stirred Up by the Media"},"content":{"rendered":"\n

Apparently, TapImmune Inc. (OTCMKTS:TPIV<\/a>) has drawn the attention of quite a lot of websites and other media outlets. More than a few articles have been published over the last few months and there have also been some interviews with Glynn Wilson, the company CEO.<\/p>\n

People are interested in TPIV<\/a><\/strong>‘s business and this, in turn, means that a lot more eyes are now focused on the stock. Unfortunately, the performance is hardly stellar. In fact it’s quite disappointing.<\/p>\n

Between September 11 and October 16, for example, TPIV<\/a><\/strong> lost more than 60% of its market cap<\/strong> when it fell from just over $1 per share to less than $0.40. It would appear that the $0.40 mark is still putting up a fight. Although the ticker broke through it at the beginning of the week, it slipped by around 5% on Wednesday and it’s currently sitting at $0.39. Nevertheless, many people probably believe that the increasing volumes will manage to stabilize the performance a little bit. If that is to happen, however, TPIV<\/a><\/strong> will need to show us something more than news coverage. Thankfully, things seem to be moving in that aspect as well. <\/p>\n

On November 18, the company announced that, in collaboration with The Vaccine & Gene Institute of Florida, they will be conducting the Phase II human trials for the treatment of breast and ovarian cancer.<\/p>\n

Hopefully, the trials will go without a hitch and hopefully, TPIV<\/a><\/strong> will soon start generating revenues. If they don’t, the continuing losses could soon start to put quite a lot of pressure on the balance sheet. The latest 10-Q, by the way, suggests that this process has already begun. On September 30, the company had an accumulated deficit of around $86 million and:<\/p>\n